Xenetic Biosciences (NASDAQ:XBIO) Stock Price Passes Above Fifty Day Moving Average – What’s Next?

Xenetic Biosciences, Inc. (NASDAQ:XBIO)’s stock price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.89 and traded as high as $2.96. Xenetic Biosciences shares last traded at $2.85, with a volume of 18,955 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Xenetic Biosciences Price Performance

The stock has a market capitalization of $6.53 million, a P/E ratio of -2.37 and a beta of 2.10. The firm has a 50-day simple moving average of $2.89 and a 200 day simple moving average of $2.81.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.The firm had revenue of $0.66 million for the quarter.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC bought a new position in Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned approximately 0.60% of Xenetic Biosciences as of its most recent SEC filing. 15.12% of the stock is currently owned by hedge funds and other institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.